Pomerantz Law Firm Launches Investigation into Investor Claims against Disc Medicine, Inc.

Investigation Announcement

Pomerantz LLP has initiated a thorough investigation regarding claims made by investors of Disc Medicine, Inc. (NASDAQ: IRON). This concern arises amid allegations of possible securities fraud and other unlawful business practices associated with the company and certain high-ranking officials. Investors who wish to know more about the investigation are encouraged to reach out to attorney Danielle Peyton directly via email or at the provided phone number.

Background Context

The scrutiny into Disc Medicine began on January 15, 2026, when reports emerged detailing troubling developments regarding a crucial drug under development. Reuters highlighted that the U.S. Food and Drug Administration (FDA) had flagged safety and efficacy issues, which subsequently led to a sharp decline in Disc's share price—dropping $6.04 per share, or approximately 7.84%, closing at $71.04.

Later, on February 13, 2026, the situation worsened when Disc announced receiving a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for the drug bitopertin, intended for treating erythropoietic protoporphyria (EPP). The FDA's letter indicated that clinical trials failed to establish a connection between the measured endpoints and the proposed treatment's efficacy. Following this news, the stock plummeted further—losing $15.70 per share, or 21.91%, to close at $55.95.

About Pomerantz LLP

Pomerantz LLP is recognized as one of the leading firms specializing in corporate, securities, and antitrust class actions. With offices across major cities like New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has established a strong reputation in advocating for victims of securities fraud and corporate misconduct. Founded over 85 years ago, Pomerantz has secured numerous multimillion-dollar settlements on behalf of its clients. Investors may find further information about the firm and its mission on its official website.

Pomerantz emphasizes its commitment to protecting investor rights and ensuring that justice is served for those affected by potential corporate wrongdoing. As the primary investigations unfold, further developments will be crucial to determine the implications for Disc Medicine, its investors, and the future of its drug programs.

Legal Disclaimer

It is important to note that this investigation is ongoing, and past results do not guarantee future outcomes. All investors are encouraged to stay informed and consider their options carefully as developments arise. For more assistance, potential class members should reach out to Pomerantz LLP directly.

For direct inquiries, Danielle Peyton from Pomerantz LLP is available at her email or phone, as mentioned above. The ongoing situation serves as a reminder of the volatility in the pharmaceutical sector and the associated risks investors must consider.